Patents by Inventor Quanhai Liu

Quanhai Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11866458
    Abstract: The invention discloses a panaxadiol glycoside derivative and a preparation method and application thereof. Such compounds show strong anti-inflammatory effects in vitro and in animal model experiments, and thus can be used to prepare anti-inflammatory drugs, especially can be used for treating asthma and COPD. In the experiment, the above-mentioned compounds have obvious effects on asthma and COPD, and the efficacy of the high-dose group is superior than that of dexamethasone and budesonide. Even under the dose much exceeding the therapeutic dose, no obvious affect on blood routine and blood glucoseis observed. It has high industrial prospects in the field of anti-inflammatory drugs, especially in the field for treating asthma and COPD.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: January 9, 2024
    Assignee: Suzhou JI ER Biological Medicine Co. Ltd.
    Inventors: Quanhai Liu, Jun Zhang
  • Publication number: 20210054019
    Abstract: The invention discloses a panaxadiol glycoside derivative and a preparation method and application thereof. Such compounds show strong anti-inflammatory effects in vitro and in animal model experiments, and thus can be used to prepare anti-inflammatory drugs, especially can be used for treating asthma and COPD. In the experiment, the above-mentioned compounds have obvious effects on asthma and COPD, and the efficacy of the high-dose group is superior than that of dexamethasone and budesonide. Even under the dose much exceeding the therapeutic dose, no obvious affect on blood routine and blood glucoseis observed. It has high industrial prospects in the field of anti-inflammatory drugs, especially in the field for treating asthma and COPD.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 25, 2021
    Applicant: SUZHOU JI ER BIOLOGICAL MEDICINE CO., LTD.
    Inventors: QUANHAI LIU, JUN ZHANG
  • Patent number: 10800733
    Abstract: Disclosed are a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the Formula I, and an application thereof in preparing drugs for regulating blood lipids.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 13, 2020
    Assignee: Shanghai Bioenergy Medicine Science & Technology Co., Ltd.
    Inventors: Yuqiong Dong, Quanhai Liu, Yu Shen, Wentao Cai
  • Patent number: 10647673
    Abstract: Disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof, preparation method thereof, and use thereof in preventing or treating fatty liver or in preparing pharmaceuticals for weight loss.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 12, 2020
    Assignee: Nanjing Bioenergy Medicine Science & Technology Co., Ltd.
    Inventors: Yuqiong Dong, Quanhai Liu, Yu Shen, Wentao Cai
  • Patent number: 10428013
    Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: October 1, 2019
    Assignees: Shanghai Institute of Phamaceutical Industry, China State Institute of Pharmaceutical Industry
    Inventors: Zhenpeng Yu, Gouping Wang, Zhen Zhang, Minyu Liu, Xiaoling Huang, Ying Liu, Lin Xiao, Li Cai, Xuejun Wu, Yifang Deng, Mianli Pan, Renhai Chen, Shenrong Tang, Quanhai Liu
  • Publication number: 20190292153
    Abstract: Disclosed is a compound represented by formula I or a pharmaceutically acceptable salt thereof, preparation method thereof, and use thereof in preventing or treating fatty liver or in preparing pharmaceuticals for weight loss.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 26, 2019
    Applicant: Nanjing Bioenergy Medicine Science & Technology Co., Ltd.
    Inventors: Yuqiong DONG, Quanhai LIU, Yu SHEN, Wentao CAI
  • Publication number: 20190292137
    Abstract: Disclosed are a compound represented by Formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, the Formula I, and an application thereof in preparing drugs for regulating blood lipids.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 26, 2019
    Applicant: Shanghai Bioenergy Medicine Science & Technology Co., Ltd.
    Inventors: Yuqiong DONG, Quanhai LIU, Yu SHEN, Wentao CAI
  • Patent number: 10238657
    Abstract: Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: March 26, 2019
    Assignee: JS INNOPHARM (SHANHAI) LTD.
    Inventors: Jintao Zhang, Quanhai Liu, Minyu Liu, Xiaoling Huang, Yifang Deng, Pengxia Yu
  • Publication number: 20180169096
    Abstract: Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: June 3, 2015
    Publication date: June 21, 2018
    Applicant: JS INNOPHARM (SHANGHAI) LTD.
    Inventors: Jintao ZHANG, Quanhai LIU, Minyu LIU, Xiaoling HUANG, Yifang DENG, Pengxia YU
  • Patent number: 9650403
    Abstract: Disclosed are a platinum (II) compound, a preparation method therefor, and a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: enabling dihydrate diammine platinum nitrate (4) to react with the carboxylate ligand derivative (5) in water, to produce a platinum (II) compound. Also provided are an application of the platinum (II) compound in preparation of an antitumor drug, and a pharmaceutical composition. The pharmaceutical composition contains an active component and a medicinal carrier, the active component containing the platinum (II) compound, and the mass percentage of the active component being 0.1%-95%. The platinum (II) compound of the present invention is well water-soluble, low toxic, easily prepared, and efficient in antitumor activity.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: May 16, 2017
    Assignees: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY
    Inventors: Baoquan Zhu, Yongzhi Shu, Jun Lin, Haifeng Hu, Quanhai Liu, Bin Zhou
  • Patent number: 9539271
    Abstract: The present invention discloses an application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of a drug for the prevention and treatment of thromboembolic diseases. The DHG is more than one type of DHG with weight-average molecular weights between 26,000 and 45,000 Da. When being intravenously or subcutaneously injected, the drug using the DHG with weight-average molecular weights between 26,000 and 45,000 Da as an active ingredient has a significant anticoagulant effect, while at the same time, has little side effects, and is effective for use in the prevention and treatment of the thromboembolic diseases. For an injection of DHG with weight-average molecular weights between 26,000 Da and 45,000 Da, the blood coagulation time is prolonged and the anticoagulant effect is enhanced as the dosage increases; the subcutaneous administration is used and is more favorable for use in the drug, and the convenience and safety of use the drug are improved.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: January 10, 2017
    Assignees: Shanghai Kairun Biology Medicine Limited Liability Company, Harbin Hongdoushan Bio-Pharm Co., Ltd., Heilongjiang Hongdoushan Pharmaceutical Co., Ltd.
    Inventors: Zhiguo Wang, Quanhai Liu, Xuehai Wu
  • Publication number: 20160194345
    Abstract: Disclosed are a platinum (II) compound, a preparation method therefor, and a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: enabling dihydrate diammine platinum nitrate (4) to react with the carboxylate ligand derivative (5) in water, to produce a platinum (II) compound. Also provided are an application of the platinum (II) compound in preparation of an antitumor drug, and a pharmaceutical composition. The pharmaceutical composition contains an active component and a medicinal carrier, the active component containing the platinum (II) compound, and the mass percentage of the active component being 0.1%-95%. The platinum (II) compound of the present invention is well water-soluble, low toxic, easily prepared, and efficient in antitumor activity.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 7, 2016
    Applicants: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY
    Inventors: Baoquan ZHU, Yongzhi SHU, Jun LIN, Haifeng HU, Quanhai LIU, Bin ZHOU
  • Publication number: 20160082051
    Abstract: The present invention discloses use of sea cucumber glycosaminoglycan in the preparation of drugs. In particular, the present invention relates to use of medical use of sea cucumber glycosaminoglycan, and more particularly to use of depolymerized sea cucumber glycosaminoglycan or natural molecular segments of sea cucumber glycosaminoglycan with a weight average molecular weight greater than 54,500 Da in the preparation of a drug for the prevention and treatment of thromboembolic diseases. Thromboembolic diseases include atherosclerotic thrombotic diseases, venous thromboembolic diseases, hypercoagulable states and postoperative thrombosis or treatment of postoperative thrombi. The present invention has a wide treatment window for thromboembolic diseases, has a higher level of safety, and has good development and research value.
    Type: Application
    Filed: May 7, 2014
    Publication date: March 24, 2016
    Applicants: Shanghai Kairun Biology Medicine Limited Liability Company, Harbin Hongdoushan Bio-Pharm Co., Ltd., Heilongjiang Hongdoushan Pharmaceutical Co., Ltd.
    Inventors: Zhiguo Wang, Quanhai Liu, Xuehai Wu
  • Patent number: 8962880
    Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 24, 2015
    Assignee: Shanghai Institute of Pharmaceutical Industry
    Inventors: Guobin Ren, Ying Liu, Jinyao Chen, Xiaoling Huang, Lin Xiao, Li Cai, Zhen Zhang, Xuejun Wu, Haiyan Sun, Quanhai Liu, Liling Jin, Minyu Liu, Yifang Deng, Zhiru Xu, Renhai Chen, Chungang Li, Xiangduan Tan, Yan Qin
  • Publication number: 20150051165
    Abstract: The present invention discloses an application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of a drug for the prevention and treatment of thromboembolic diseases. The DHG is more than one type of DHG with weight-average molecular weights between 26,000 and 45,000 Da. When being intravenously or subcutaneously injected, the drug using the DHG with weight-average molecular weights between 26,000 and 45,000 Da as an active ingredient has a significant anticoagulant effect, while at the same time, has little side effects, and is effective for use in the prevention and treatment of the thromboembolic diseases. For an injection of DHG with weight-average molecular weights between 26,000 Da and 45,000 Da, the blood coagulation time is prolonged and the anticoagulant effect is enhanced as the dosage increases; the subcutaneous administration is used and is more favorable for use in the drug, and the convenience and safety of use the drug are improved.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 19, 2015
    Applicants: Shanghai Kairun Biology Medicine Limited Liability Company, Harbin Hongdoushan Bio-Pharm Co., Ltd., Heilongjiang Hongdoushan Pharmaceutical Co., Ltd
    Inventors: Zhiguo Wang, Quanhai Liu, Xuehai Wu
  • Publication number: 20140243553
    Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 28, 2014
    Applicant: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
    Inventors: Guobin Ren, Ying Liu, Jinyao Chen, Xiaoling Huang, Lin Xiao, Li Cai, Zhen Zhang, Xuejun Wu, Haiyan Sun, Quanhai Liu, Liling Jin, Minyu Liu, Yifang Deng, Zhiru Xu, Renhai Chen, Chungang Li, Xiangduan Tan, Yan Qin
  • Patent number: 8742167
    Abstract: A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: June 3, 2014
    Assignee: Shanghai Institute of Pharmaceutical Industry
    Inventors: Ying Liu, Quanhai Liu, Yan Qin, Tong Wu, Zhiru Xu, Min-yu Liu, Fei Li, Yan Li, Michael J. Newman
  • Publication number: 20140128463
    Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.
    Type: Application
    Filed: June 25, 2012
    Publication date: May 8, 2014
    Applicants: China State Institute of Pharmaceutic Industry, Shanghai Institute of Pharmaceutical Industry
    Inventors: Zhenpeng Yu, Gouping Wang, Zhen Zhang, Minyu Liu, Xiaoling Huang, Ying Liu, Lin Xiao, Li Cai, Xuejun Wu, Yifang Deng, Mianli Pan, Renhai Chen, Shenrong Tang, Quanhai Liu
  • Patent number: 8258176
    Abstract: The invention discloses a dithiolopyrrolone compound represented by formula I or its pharmaceutically acceptable salts, wherein X1, R1, R2, R3, R4 are defined as in the description. The invention also discloses the preparation of such compounds, and the use of such compounds in preparation of medicaments for increasing peripheral white blood cells and in preparation of ancillary medicaments for inhibiting the decrease of peripheral white blood cells in radiotherapy or chemotherapy.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: September 4, 2012
    Assignees: Shanghai Institute of Pharmaceutical Industry, Shanghai Modern Pharmaceutical Co., Ltd.
    Inventors: Guoping Wang, Quanhai Liu, Haiyan Sun, Wei Wu, Jian Hou, Lin Yao, Chungang Li, Minyu Liu, Fei Li, Xuejun Wu, Shuai Zhao
  • Publication number: 20100331413
    Abstract: A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.
    Type: Application
    Filed: January 8, 2009
    Publication date: December 30, 2010
    Inventors: Ying Liu, Quanhai Liu, Yan Qin, Tong Wu, Zhiru Xu, Min-yu Liu, Fei Li, Yan Li, Michael J. Newman